ContextLogic Inc - Ordinary Shares - Class A

ContextLogic Inc - Ordinary Shares - Class A

LOGC

Get informed when a big investor buys or sells

+ Follow
Market Cap$245.2M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
ContextLogic Inc - Ordinary Shares - Class AContextLogic Inc - Ordinary Shares - Class A-82.1-3%-0.3
$0.00

Current Fair Value

100% downside

Overvalued by 100% based on the discounted cash flow analysis.

Share Statistics

Market cap$245.20 Million
Enterprise Value$443.70 Million
Dividend Yield$- (-)
Earnings per Share$-1.09
Beta2.11
Outstanding Shares45,730,500

Return

Return on Equity2.83%ROE
Return on Assets2.15%
Return on Invested Capital-2.43%

Valuation & Multiples

P/E Ratio-82.13P/E Ratio
PEG15.64PEG
Price to Sales-Price to Sales
Price to Book Ratio0.56Price to Book Ratio
Enterprise Value to Revenue13.69
Enterprise Value to EBIT-19.2
Enterprise Value to Net Income21
Total Debt to Enterprise0.47
Debt to Equity0.28Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 15, 2026
EPS Estimate
$-0.04
Average shareholder expectation
Revenue Estimate
$32.40 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$-0.04
Average shareholder expectation
Revenue Estimate
$22.48 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.40%▲ 2.23%
Total Invested$4.85M▲ 1828.26%
Investors Holding2▲ 1.00%

ESG Score

No data

About LogicBio Therapeutics Inc

39 employees
CEO: Frederic Chereau

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a...